Lung cancer survival rates are up thanks to immunotherapy, other ... - NPR
Apr 12, 2024 — Lung cancer remains the most lethal form of the disease, killing about 135,000 Americans a year – more than breast, prostate and colon cancer combined – which is why many people still think of...
Targeted Drug Stops Lung Cancer Growth for Five Years in Over …
Jun 13, 2024 — A study shows that lorlatinib (Lobrena) stops lung cancer growth and spread for 5 years or more in over half of people with ALK gene mutation. Learn how this drug outperforms crizotinib and how molecular testing can help guide treatment options.
Lung Cancer News -- ScienceDaily
Stay updated on the latest news and discoveries about lung cancer, the leading cause of cancer death worldwide. Read about new treatments, prevention, diagnosis, and research breakthroughs from...
Lung cancer treatment: Pfizer's Lorbrena extends life in ... - NBC News
May 31, 2024 — Pfizer’s lung cancer drug Lorbrena can extend life for patients with a rare form of the disease for years longer than other drugs, according to new research published Friday. The drug treats a...
Tarlatamab for Previously Treated Small Cell Lung Cancer
Dec 1, 2023 — UPDATE: On May 16, the Food and Drug Administration approved tarlatamab (Imdelltra) to treat people with extensive-stage small cell lung cancer whose disease has worsened while receiving or after receiving platinum-based chemotherapy. The approval was based on findings from the DeLLphi-301 clinical trial described below. Under the accelerated approval, Amgen, the drug’s maker, must conduct ...
Osimertinib Improves Survival in Lung Cancer - NCI
Jul 5, 2023 — A large study of people with early-stage lung cancer and EGFR mutations found that osimertinib, a targeted drug, increased their overall survival after surgery. However, some oncologists questioned the trial design and the benefits of giving osimertinib to all patients.
Repotrectinib Shrinks ROS1-Positive NSCLC Tumors - NCI
Feb 16, 2024 — Repotrectinib is a new drug that can shrink tumors in people with advanced lung cancer with ROS1 fusions, a genetic change that makes the cancer cells grow out of control. The drug was approved by FDA in 2023 and can overcome some resistance mutations that other ROS1-targeted drugs cannot.
FDA Approves New Treatment for Non-Small-Cell Lung Cancer - WebMD
Aug 21, 2024 — The FDA has approved a new chemotherapy-free combination of Lazcluze and Rybrevant for advanced non-small-cell lung cancer that targets a common gene mutation. The combination showed longer...
US lung cancer survival rates rise, but it’s still the leading ... - CNN
Nov 14, 2023 — CNN — Over the past five years, the five-year survival rate for lung cancer in the US has increased a significant 22%, according to a new report from the American Lung Association. But the...
After Four Decades, a Breakthrough for Lung Cancer
Sotorasib, a drug that blocks a cancer-causing protein in KRAS, was approved by the FDA in 2021 based on an international clinical trial co-led by MSK. The trial showed remarkable responses and survival for patients with advanced lung cancer who had exhausted other options.